Bristol-Myers Squibb v. Zydus: Dasatinib Patent Dispute Dismissed
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Bristol-Myers Squibb Company v. Zydus Cadila and Zydus Lifesciences Limited |
| Case Number | 1:23-cv-21098 (D.N.J.) |
| Court | U.S. District Court for the District of New Jersey |
| Duration | Oct 2023 – Mar 2024 153 days |
| Outcome | Dismissed Without Prejudice |
| Patents at Issue | |
| Accused Products | SPRYCEL® (dasatinib) |
Case Overview
The Parties
⚖️ Plaintiff
A global biopharmaceutical leader with a robust oncology portfolio. SPRYCEL® (dasatinib) is one of its flagship cancer therapies, making patent protection a high-priority enforcement objective.
🛡️ Defendant
Prominent Indian generic pharmaceutical manufacturers with a well-established U.S. market presence, known for aggressively pursuing ANDA-based generic approvals.
The Patents at Issue
This case involved two patents protecting SPRYCEL® (dasatinib), a blockbuster oncology therapy, and raised critical questions about generic market entry strategy in the branded pharmaceutical space.
- • US 8,680,103 — A later-filed patent, likely covering formulation, polymorph, or method-of-use aspects of SPRYCEL®.
- • US 7,491,725 — An earlier patent, potentially covering core chemical compound or synthetic process claims related to dasatinib.
Developing a generic drug?
Check if your formulation or manufacturing process might infringe these or related patents.
The Verdict & Legal Analysis
Outcome
The case concluded with a **stipulated dismissal without prejudice** on March 13, 2024. No damages were awarded, and no injunctive relief was issued. The “without prejudice” designation preserves BMS’s right to refile the same claims in the future, should circumstances warrant.
Key Legal Issues
This action was classified as an **infringement action** under the Hatch-Waxman Act framework, triggered by Zydus’s Paragraph IV ANDA certification. The filing of such a suit automatically triggers a **30-month stay** of FDA approval for the generic product. The swift resolution by mutual agreement, rather than adjudication on the merits, is consistent with licensing negotiations, settlement terms, or a commercial agreement between the parties, though specific terms remain undisclosed.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in oncology drug development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this pharmaceutical litigation.
- View all related patents in the dasatinib technology space
- See which companies are most active in oncology drug patents
- Understand claim construction patterns for pharmaceutical claims
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your generic drug or novel therapeutic.
- Input your drug’s chemical structure or formulation details
- AI identifies potentially blocking pharmaceutical patents
- Get actionable risk assessment report for market entry
High Risk Area
Oncology drugs with similar active ingredients or formulations
Layered IP Protection
BMS uses multi-patent assertion strategies
Strategic Options
Available for generic market entry
✅ Key Takeaways
Dismissal without prejudice in Hatch-Waxman cases preserves future enforcement rights – a critical drafting distinction from with-prejudice settlements.
Search related case law →New Jersey District Court remains the preferred venue for pharmaceutical patent infringement actions, offering judicial expertise and procedural efficiency.
Explore precedents →Multi-patent assertion strategies strengthen leverage in ANDA litigation negotiations for branded pharma.
Analyze pharma patent portfolios →Frequently Asked Questions
The case involved U.S. Patent Nos. 8,680,103 and 7,491,725, both associated with SPRYCEL® (dasatinib), BMS’s oncology therapy for leukemia treatment.
The parties filed a Stipulation and Order of Dismissal Without Prejudice, signed March 13, 2024. No merits ruling was issued; the specific terms of resolution were not publicly disclosed.
The without-prejudice dismissal preserves BMS’s right to refile, signaling conditional resolution. IP practitioners should monitor the FDA Orange Book and related ANDA filings for signals of negotiated generic entry timelines.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER — Case No. 1:23-cv-21098, D.N.J.
- USPTO Patent Center — Patent Details (U.S. Patent Nos. 8,680,103 and 7,491,725)
- Cornell Legal Information Institute — Hatch-Waxman Act
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.